{"url":"https://lda.gov/api/v1/filings/db13622d-fa0c-47fc-9ca9-74ed082026f3/","filing_uuid":"db13622d-fa0c-47fc-9ca9-74ed082026f3","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/db13622d-fa0c-47fc-9ca9-74ed082026f3/print/","filing_document_content_type":"text/html","income":null,"expenses":"840000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Beth Anne Cole","dt_posted":"2026-04-20T18:54:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 New Jersey Ave NW","registrant_address_2":"Suite 850","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":16032,"url":"https://lda.gov/api/v1/registrants/16032/","house_registrant_id":31463,"name":"ASSOCIATION FOR ACCESSIBLE MEDICINES","description":"Association representing the interests of the generic pharmaceutical industry.","address_1":"601 New Jersey Ave NW","address_2":"Suite 850","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MARK RATNER","contact_telephone":"+1 202-249-7100","dt_updated":"2026-07-29T08:15:25.555128-04:00"},"client":{"id":121533,"url":"https://lda.gov/api/v1/clients/121533/","client_id":12,"name":"ASSOCIATION FOR ACCESSIBLE MEDICINES","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation. CMS RFC on Domestic Manufacturing. PBM Bid Transparency.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153755,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"KEETON","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Generic Drug Reporting Requirement Language in Public Law No. 119-60: National Defense Authorization Act for Fiscal Year 2026. Public Law No. 119-60: National Defense Authorization Act for Fiscal Year 2026. H.R.1396/S.1891: Producing Incentives for Long-term Production of Lifesaving Supply of Medicine (PILLS) Act. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062: RAPID Reserve Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. S.1414/H.R.__: Expedited Access to Biosimilars Act. S.3469: BIOSECURE Act of 2025. Quotas on Controlled Substances. Hassan Purple Book Proposal. S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act. PBM Bid Transparency. H.R.7148 - Consolidated Appropriations Act, 2026 as it relates to PBM reforms and Q1/Q2.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153755,"prefix":null,"prefix_display":null,"first_name":"ALEX","nickname":null,"middle_name":null,"last_name":"KEETON","suffix":null,"suffix_display":null},"covered_position":"Senior Legislative Assistant / Deputy Communications Director / Assistant to the Chief of Staff / Legislative Correspondent / Intern - Congressman Lincoln Davis","new":true},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. H.R.4570/S.1097: Interagency Patent Coordination and Improvement Act of 2025. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"General Trade Issues. Drug Supply Chain. Rules of Origin. Country of Origin Labeling. Tariffs on Generic Medicines. Quotas on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars. India Trade Negotiations. United States-Mexico-Canada Agreement. S.3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70517,"prefix":null,"prefix_display":null,"first_name":"KARIN","nickname":null,"middle_name":null,"last_name":"HESSLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144371,"prefix":null,"prefix_display":null,"first_name":"ILHAAM","nickname":null,"middle_name":null,"last_name":"JAFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148335,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142070,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"KELBEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151900,"prefix":null,"prefix_display":null,"first_name":"MARK","nickname":null,"middle_name":null,"last_name":"RATNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":184,"name":"U.S. Customs & Border Protection"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}